Pharma Pioneer

International Wound Journal Publishes Microbion's Phase 1b Study on Pravibismane for Treating Diabetic Foot Ulcer Infections

17 May 2024
3 min read

A recent Phase 1b clinical trial of topical pravibismane for managing moderate to severe diabetic foot ulcers has shown promising results. The study, published in the International Wound Journal, revealed that the treatment was safe and well-tolerated across all tested dosages. It also indicated a potential for greater ulcer size reduction and a lower likelihood of amputations when compared to a placebo.

Microbion Corporation, the developer of pravibismane, highlighted the drug's unique attributes, including its broad-spectrum anti-infective, antibiofilm, and immuno-modulatory capabilities. The study's primary focus was on the safety profile of the drug when used as an adjunct to standard care for 2 to 3 weeks. Although not designed to prove statistical efficacy, the study showed positive trends in clinical efficacy. 

Dr. Benjamin A. Lipsky, the main author of the study, expressed enthusiasm about the findings, noting the need for new treatments with multiple modes of action to address the challenges of infected chronic wounds. Dr. David G. Armstrong, a co-author, emphasized the importance of new agents to expedite wound closure, especially considering the current reliance on systemic antibiotics followed by secondary treatments. The study included 39 participants who received pravibismane and 13 who were given a placebo. 

Pravibismane was shown to be well-tolerated with minimal systemic absorption and no serious adverse events. Subjects treated with pravibismane experienced nearly a threefold reduction in ulcer size compared to the placebo group. Additionally, the pravibismane group had a significantly lower rate of lower limb amputations related to diabetic ulcers. Microbion has also completed a Phase 2 study, which assessed a higher concentration and a 12-week treatment duration of topical pravibismane. This study aimed to evaluate safety and tolerability, with secondary objectives focused on achieving complete wound closure. 

Microbion is a clinical-stage pharmaceutical company focused on developing innovative therapeutic compounds for rare and severe diseases. Pravibismane, their leading drug candidate, is undergoing Phase 2 development for chronic wound treatment, with other forms in various stages of development for orthopedic infections and chronic lung diseases. The drug has received significant financial support and has been granted several FDA designations to facilitate its development and potential market entry.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Positive Clinical Results from TPST-1120 Phase 1 Trial for Advanced Solid Tumors Published in Cancer Research Journal
Pharma Pioneer
3 min read
Positive Clinical Results from TPST-1120 Phase 1 Trial for Advanced Solid Tumors Published in Cancer Research Journal
17 May 2024
TPST-1120, a novel oral PPAR⍺ inhibitor, has shown promising results in treating cancers that are resistant to PD-1 inhibitors and those with weakened immune systems.
Read →
ADC Therapeutics Provides LOTIS-7 Trial Updates on ZYNLONTA Combos for Relapsed/Refractory B-cell Lymphoma
Pharma Pioneer
2 min read
ADC Therapeutics Provides LOTIS-7 Trial Updates on ZYNLONTA Combos for Relapsed/Refractory B-cell Lymphoma
17 May 2024
LOTIS-7 Phase 1b Trial Completes Dose Escalation: ZYNLONTA® and Bispecific Antibodies for Non-Hodgkin Lymphoma Patients, No Severe Side Effects Observed.
Read →
Ocugen Receives DSMB Approval for Medium Dose Enrollment in Phase 1/2 Trial of OCU410 Gene Therapy for Geographic Atrophy
Pharma Pioneer
2 min read
Ocugen Receives DSMB Approval for Medium Dose Enrollment in Phase 1/2 Trial of OCU410 Gene Therapy for Geographic Atrophy
17 May 2024
Ocugen, Inc. has received approval from the Data and Safety Monitoring Board (DSMB) to advance to the medium dose cohort in the Phase 1/2 clinical trial for OCU410.
Read →
Geneos Therapeutics Reveals Favorable Phase 1/2 Results for Customized Cancer Vaccine in GT-30 Trial
Pharma Pioneer
2 min read
Geneos Therapeutics Reveals Favorable Phase 1/2 Results for Customized Cancer Vaccine in GT-30 Trial
17 May 2024
Geneos Therapeutics has reported successful results from its GT-30 clinical trial, showcasing the safety and effectiveness of a personalized therapeutic cancer vaccine (PTCV) for patients with advanced hepatocellular carcinoma (HCC).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.